SG10201902664RA - Combination therapy for treating cancer - Google Patents
Combination therapy for treating cancerInfo
- Publication number
- SG10201902664RA SG10201902664RA SG10201902664RA SG10201902664RA SG10201902664RA SG 10201902664R A SG10201902664R A SG 10201902664RA SG 10201902664R A SG10201902664R A SG 10201902664RA SG 10201902664R A SG10201902664R A SG 10201902664RA SG 10201902664R A SG10201902664R A SG 10201902664RA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapy
- treating cancer
- inhibitors
- cancer
- ezh
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 102000011787 Histone Methyltransferases Human genes 0.000 abstract 1
- 108010036115 Histone Methyltransferases Proteins 0.000 abstract 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 abstract 1
- 229940124304 VEGF/VEGFR inhibitor Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 abstract 1
- 229960001796 sunitinib Drugs 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150185P | 2015-04-20 | 2015-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201902664RA true SG10201902664RA (en) | 2019-04-29 |
Family
ID=57143391
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201902664RA SG10201902664RA (en) | 2015-04-20 | 2016-04-20 | Combination therapy for treating cancer |
| SG11201708286PA SG11201708286PA (en) | 2015-04-20 | 2016-04-20 | Combination therapy for treating cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708286PA SG11201708286PA (en) | 2015-04-20 | 2016-04-20 | Combination therapy for treating cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10456407B2 (he) |
| EP (1) | EP3285773A4 (he) |
| JP (3) | JP2018513865A (he) |
| CN (1) | CN108135908A (he) |
| AU (3) | AU2016252546A1 (he) |
| CA (1) | CA2983265A1 (he) |
| EA (1) | EA201792304A1 (he) |
| IL (1) | IL255060A0 (he) |
| MX (1) | MX2017013142A (he) |
| SG (2) | SG10201902664RA (he) |
| WO (1) | WO2016172199A1 (he) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019126908A (ru) * | 2012-04-13 | 2020-01-13 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| KR102473113B1 (ko) | 2013-12-06 | 2022-12-01 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| AU2016252546A1 (en) * | 2015-04-20 | 2017-11-02 | Epizyme, Inc. | Combination therapy for treating cancer |
| US20180311251A1 (en) | 2015-06-10 | 2018-11-01 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
| JP2019503391A (ja) * | 2016-01-29 | 2019-02-07 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| AU2017273726B2 (en) | 2016-06-01 | 2023-10-19 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| MA45406A (fr) | 2016-06-17 | 2019-04-24 | Epizyme Inc | Inhibiteurs d'ezh2 pour traiter le cancer |
| US11214561B2 (en) | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| WO2018183885A1 (en) * | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN110944628A (zh) | 2017-06-02 | 2020-03-31 | Epizyme股份有限公司 | 使用ezh2抑制剂治疗癌症 |
| CA3074720A1 (en) * | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2020055663A1 (en) * | 2018-09-11 | 2020-03-19 | The Texas A&M University System | L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2) |
| CN118236503A (zh) * | 2019-07-24 | 2024-06-25 | 星座制药公司 | 用于治疗癌症的ezh2抑制联合疗法 |
| TW202126302A (zh) * | 2019-09-30 | 2021-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｅｚｈ２抑制劑與免疫檢查點抑制劑、酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US437451A (en) * | 1890-09-30 | Bee-swarm er | ||
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| JP6389036B2 (ja) | 2010-09-10 | 2018-09-12 | エピザイム インコーポレイテッド | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| JP2014511389A (ja) | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換６，５−縮合二環式ヘテロアリール化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| HUE060881T2 (hu) | 2012-04-13 | 2023-04-28 | Epizyme Inc | Sóforma az EZH2 gátláshoz |
| RU2019126908A (ru) * | 2012-04-13 | 2020-01-13 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| CA2887243C (en) * | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| EP2906537B1 (en) | 2012-10-15 | 2020-03-11 | Epizyme, Inc. | Substituted benzene compounds |
| AU2013361079B2 (en) | 2012-12-21 | 2018-07-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| WO2014100646A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| JP2016516046A (ja) | 2013-03-14 | 2016-06-02 | ジェネンテック， インコーポレイテッド | がんの治療方法及びがん薬物耐性を阻止する方法 |
| WO2014172044A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| WO2014144747A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| BR112015025711A8 (pt) | 2013-04-08 | 2019-12-17 | Janssen Pharmaceutica Nv | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer |
| WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
| PL3057962T3 (pl) | 2013-10-16 | 2024-01-29 | Epizyme, Inc. | Postać soli chlorowodorku do inhibicji ezh2 |
| AU2014337121A1 (en) | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
| KR102473113B1 (ko) | 2013-12-06 | 2022-12-01 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| SG10201811128RA (en) | 2014-06-17 | 2019-01-30 | Epizyme Inc | Ezh2 inhibitors for treating lymphoma |
| WO2015200650A1 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| NZ730365A (en) | 2014-10-16 | 2024-03-22 | Epizyme Inc | Method for treating cancer |
| MX2017006089A (es) | 2014-11-17 | 2017-12-11 | Epizyme Inc | Metodo para tratar el cancer. |
| AU2016252546A1 (en) * | 2015-04-20 | 2017-11-02 | Epizyme, Inc. | Combination therapy for treating cancer |
-
2016
- 2016-04-20 AU AU2016252546A patent/AU2016252546A1/en not_active Abandoned
- 2016-04-20 EP EP16783757.4A patent/EP3285773A4/en active Pending
- 2016-04-20 CA CA2983265A patent/CA2983265A1/en active Pending
- 2016-04-20 SG SG10201902664RA patent/SG10201902664RA/en unknown
- 2016-04-20 EA EA201792304A patent/EA201792304A1/ru unknown
- 2016-04-20 JP JP2017554892A patent/JP2018513865A/ja active Pending
- 2016-04-20 CN CN201680028899.5A patent/CN108135908A/zh active Pending
- 2016-04-20 SG SG11201708286PA patent/SG11201708286PA/en unknown
- 2016-04-20 MX MX2017013142A patent/MX2017013142A/es unknown
- 2016-04-20 WO PCT/US2016/028425 patent/WO2016172199A1/en active Application Filing
- 2016-04-20 US US15/567,838 patent/US10456407B2/en active Active
-
2017
- 2017-10-16 IL IL255060A patent/IL255060A0/he unknown
-
2019
- 2019-09-06 US US16/562,683 patent/US11026949B2/en active Active
-
2021
- 2021-04-28 US US17/243,149 patent/US20210353632A1/en not_active Abandoned
- 2021-06-01 JP JP2021092006A patent/JP2021130700A/ja active Pending
- 2021-06-30 AU AU2021204515A patent/AU2021204515B2/en active Active
-
2023
- 2023-07-07 JP JP2023111904A patent/JP2023126957A/ja active Pending
- 2023-10-24 AU AU2023254894A patent/AU2023254894A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3285773A1 (en) | 2018-02-28 |
| EA201792304A1 (ru) | 2018-03-30 |
| JP2023126957A (ja) | 2023-09-12 |
| AU2023254894A1 (en) | 2023-11-16 |
| JP2021130700A (ja) | 2021-09-09 |
| AU2021204515B2 (en) | 2023-08-10 |
| US11026949B2 (en) | 2021-06-08 |
| US20210353632A1 (en) | 2021-11-18 |
| JP2018513865A (ja) | 2018-05-31 |
| US20200101081A1 (en) | 2020-04-02 |
| IL255060A0 (he) | 2017-12-31 |
| CA2983265A1 (en) | 2016-10-27 |
| MX2017013142A (es) | 2019-03-28 |
| SG11201708286PA (en) | 2017-11-29 |
| AU2021204515A1 (en) | 2021-07-29 |
| US20180289717A1 (en) | 2018-10-11 |
| AU2016252546A1 (en) | 2017-11-02 |
| US10456407B2 (en) | 2019-10-29 |
| EP3285773A4 (en) | 2019-04-10 |
| WO2016172199A1 (en) | 2016-10-27 |
| CN108135908A (zh) | 2018-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| ZA201808562B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
| EA202091908A3 (ru) | Комбинированная терапия для лечения онкологического заболевания |